Literature DB >> 19591643

NAC: still the way to go.

Amit K Gupta, Gar M Chan, Howard A Greller, Mark K Su.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591643      PMCID: PMC2717452          DOI: 10.1186/cc7905

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

We would like to thank Yang and colleagues for their attempt to determine the possibility of delayed hepatic recovery with N-acetylcysteine (NAC) administration in acetaminophen-induced hepatotoxicity [1]. We are concerned, however, about the possible consequences that may arise from their conclusions. Owing to the wide availability of acetaminophen, intentional and unintentional overdoses are one of the leading causes of liver failure in the world [2]. NAC is currently a highly effective and safe antidote to treat acute acetaminophen overdose, and is most efficacious when administered within 8 hours of ingestion [3]. Furthermore, one landmark study showed that even in patients who presented with delayed acetaminophen-induced fulminant hepatic failure, intravenous NAC administration improved survival versus control individuals (48% vs. 20%) [4]. Another study found that the infusion of acetylcysteine in patients with acetaminophen-induced liver failure resulted in an increase in mean oxygen delivery and in an increased mean arterial pressure [5]. It is difficult to believe that the mouse model of Yang and colleagues has any correlation to humans, since the already established human data are so overwhelmingly positive. The amount of acetaminophen administered in their study caused hepatotoxicity but did not induce death, and therefore is not applicable to real-life situations where people may ingest potentially fatal doses of acetaminophen. It is not clear to us why the authors came to explore this study topic. The conclusions drawn from their article are potentially dangerous and should be viewed with caution and scepticism.

Authors' response

Runkuan Yang, Keita Miki, Xin He, Meaghan E Killeen and Mitchell P Fink We would like to point out the following factors. Firstly, NAC treatment was effective at the 24 hours timepoint in our study. Also, the main treatment duration in the paper of Keays and colleagues was 20 hours [4]. Even though a low dose of NAC infusion was continued after the main treatment, this therapy was discontinued when patients recovered from encephalopathy. It is not clear for how long this NAC treatment was given in surviving patients and in nonsurviving patients. Finally, Harrison and colleagues' patients were treated with NAC for 4 hours and 15 minutes [5] – the treatment was therefore not prolonged. Acetaminophen is frequently used by patients with chronic pain. Acetaminophen hepatotoxicity in these patients is treated with NAC for longer than the standard 20 hours in some hospitals. At present, NAC is also used to treat nonacetaminophen-induced hepatotoxicity [6,7]. The median duration of NAC administration in children with nonacetaminophen-induced acute liver injury is 5 days (range, 1 to 77 days) [7]. There are, however, only limited data available on the efficacy and safety of NAC. It is therefore important to know the safety and efficacy of prolonged NAC therapy.

Abbreviations

NAC: N-acetylcysteine.

Competing interests

The authors declare that they have no competing interests.
  7 in total

1.  Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)

Authors:  M J Smilkstein; G L Knapp; K W Kulig; B H Rumack
Journal:  N Engl J Med       Date:  1988-12-15       Impact factor: 91.245

2.  Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure.

Authors:  Christine Kortsalioudaki; Rachel M Taylor; Paul Cheeseman; Sanjay Bansal; Giorgina Mieli-Vergani; Anil Dhawan
Journal:  Liver Transpl       Date:  2008-01       Impact factor: 5.799

3.  Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial.

Authors:  R Keays; P M Harrison; J A Wendon; A Forbes; C Gove; G J Alexander; R Williams
Journal:  BMJ       Date:  1991-10-26

4.  Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure.

Authors:  P M Harrison; J A Wendon; A E Gimson; G J Alexander; R Williams
Journal:  N Engl J Med       Date:  1991-06-27       Impact factor: 91.245

5.  Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model.

Authors:  Tri C Tong; Mark Hernandez; William H Richardson; David P Betten; Michael Favata; Robert H Riffenburgh; Richard F Clark; David A Tanen
Journal:  Ann Emerg Med       Date:  2007-06-07       Impact factor: 5.721

Review 6.  Acetaminophen hepatotoxicity and acute liver failure.

Authors:  Linda J Chun; Myron J Tong; Ronald W Busuttil; Jonathan R Hiatt
Journal:  J Clin Gastroenterol       Date:  2009-04       Impact factor: 3.062

7.  Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity.

Authors:  Runkuan Yang; Keita Miki; Xin He; Meaghan E Killeen; Mitchell P Fink
Journal:  Crit Care       Date:  2009-04-09       Impact factor: 9.097

  7 in total
  1 in total

1.  An oxidative environment promotes growth of Mycobacterium abscessus.

Authors:  Rebecca E Oberley-Deegan; Brittany W Rebits; Michael R Weaver; Angela K Tollefson; Xiyuan Bai; Mischa McGibney; Alida R Ovrutsky; Edward D Chan; James D Crapo
Journal:  Free Radic Biol Med       Date:  2010-08-31       Impact factor: 7.376

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.